NO20061584L - Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister - Google Patents

Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister

Info

Publication number
NO20061584L
NO20061584L NO20061584A NO20061584A NO20061584L NO 20061584 L NO20061584 L NO 20061584L NO 20061584 A NO20061584 A NO 20061584A NO 20061584 A NO20061584 A NO 20061584A NO 20061584 L NO20061584 L NO 20061584L
Authority
NO
Norway
Prior art keywords
substituted
alkyl
hydrogen
carbonylamino
cycloalkyl
Prior art date
Application number
NO20061584A
Other languages
English (en)
Inventor
Brian Michael Mathes
Daniel Timothy Kohlman
Yao-Chang Xu
Michael Philip Cohen
Bai-Ping Ying
Deanna Piatt Zacherl
Deyi Zhang
Sandra Ann Filla
Kevin John Hudziak
Maria-Jesus Blanco-Pillado
Dana Rae Benesh
Frantz Victor
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20061584L publication Critical patent/NO20061584L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

Foreliggende oppfinnelse angår forbindelser med formel I eller et farmasøytisk akseptabelt syreaddisjonssalt derav, hvorr X er -C(R3c)= eller -N=, R1 er C2-C6 alkyl, substituert C2-C6 alkyl, C3-C7 sykloalkyl, substituert C3-C7 sykloalkyl, fenyl, substituert fenyl, heterosykel eller substituert heterosykel, R2 er hydrogen, Ci-Cj-n-alkyl, Cj-C6-sykloalkyl-Ci-C3-alkyl eller en gruppe med formel II forutsatt at når R C2-C6 alkyl eller susbtituert C2-C6 alkyl er R2 hydrogen eller metyl; R3a, R3b og, når X er -C(R3c)=, er R3c hver uavhengig hydrogen, fluor eller metyl, forutsatt at ikke mer enn en av R3a, R3b og R3c kan være forskjellig fra hydrogen, R4 er hydrogen eller C1-C3 alkyl, R5 er hydrogen, CrC3 alkyl eller C3-C6 sykloalkylkarbonyl, forutsatt at når R3a er forskjellig fra hydrogen er R5 hydrogen; R6 er hydrogen eller C|-C6 alkyl, og n er et heltall på fra 1 til 6 inklusive Forbindelsene ifølge oppfinnelsen er anvendelige for aktivering av 5-HTiF-reseptorer, inhibering av neuronal proteinekstravasasjon og for behandling eller hindring av migrene hos et pattedyr.
NO20061584A 2003-09-12 2006-04-07 Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister NO20061584L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50278003P 2003-09-12 2003-09-12
PCT/US2004/025607 WO2005035499A1 (en) 2003-09-12 2004-09-03 Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists

Publications (1)

Publication Number Publication Date
NO20061584L true NO20061584L (no) 2006-06-06

Family

ID=34434850

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061584A NO20061584L (no) 2003-09-12 2006-04-07 Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister

Country Status (30)

Country Link
US (3) US7291632B2 (no)
EP (1) EP1663971B1 (no)
JP (1) JP4700614B2 (no)
KR (1) KR100777875B1 (no)
CN (1) CN1849307B (no)
AR (1) AR045619A1 (no)
AT (1) ATE538093T1 (no)
AU (1) AU2004280320B2 (no)
BR (1) BRPI0414241A (no)
CA (1) CA2537936C (no)
CR (1) CR8275A (no)
CY (1) CY1112475T1 (no)
DK (1) DK1663971T3 (no)
EA (1) EA011274B1 (no)
EC (1) ECSP066415A (no)
ES (1) ES2379665T3 (no)
IL (1) IL173521A (no)
MA (1) MA28212A1 (no)
MX (1) MXPA06002767A (no)
MY (1) MY144623A (no)
NO (1) NO20061584L (no)
NZ (1) NZ545049A (no)
PE (1) PE20050350A1 (no)
PL (1) PL1663971T3 (no)
PT (1) PT1663971E (no)
SI (1) SI1663971T1 (no)
TW (1) TWI340740B (no)
UA (1) UA82711C2 (no)
WO (1) WO2005035499A1 (no)
ZA (1) ZA200602072B (no)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI263497B (en) 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists
DE102005055892A1 (de) * 2005-11-22 2007-05-24 Henkel Kgaa Neue Kupplerkomponenten
MX2011010359A (es) * 2009-04-02 2012-02-23 Colucid Pharmaceuticals Inc Composición de 2,4,6-trifluoro-n-[6-(1-metilo-piperidina-4-carboni lo)-piridina-2-ilo]-benzamida.
US20120142932A1 (en) * 2009-09-08 2012-06-07 Koji Kawamura Method for manufacturing 4-(5-methylpyridin-2-ylamino)piperidine-1-carboxylic acid derivative
CA2795062A1 (en) 2010-04-02 2011-10-06 Colucid Pharmaceuticals, Inc. Compositions and methods of synthesis of pyridinoylpiperidine 5-ht1f agonists
US20160168132A1 (en) * 2013-07-31 2016-06-16 Minoryx Therapeutics S.L. Di(hetero)arylamides and sulfonamides, methods for their preparation and therapeutic uses thereof
CN109596521A (zh) * 2018-02-11 2019-04-09 中国科学院海洋研究所 磷钼蓝分光光度法中还原剂的保存方法
CA3107145A1 (en) 2018-08-24 2020-02-27 Sunshine Lake Pharma Co., Ltd. Pyridinylmethylenepiperidine derivatives and uses thereof
AR119319A1 (es) 2019-07-09 2021-12-09 Lilly Co Eli Procesos e intermediario para la preparación a gran escala de hemisuccinato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida y preparación de acetato de 2,4,6-trifluoro-n-[6-(1-metil-piperidina-4-carbonil)-piridin-2-il]-benzamida
CN111004214B (zh) * 2019-11-22 2021-06-08 广东东阳光药业有限公司 吡啶酰基哌啶衍生物及其用途
CN110845402B (zh) * 2019-11-22 2023-05-09 广东东阳光药业有限公司 吡啶亚甲基哌嗪衍生物及其用途
WO2021097781A1 (zh) * 2019-11-22 2021-05-27 广东东阳光药业有限公司 吡啶亚甲基哌啶衍生物及其用途
CN113045540B (zh) * 2019-12-27 2024-02-13 上海天慈国际药业有限公司 一种拉司米地坦的制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5356904A (en) * 1992-10-07 1994-10-18 Merck & Co., Inc. Carbostyril oxytocin receptor antagonists
DE4320484A1 (de) * 1993-06-21 1994-12-22 Dornier Gmbh Steuerbares Supraleiter-Bauelement
US5521196A (en) 1994-10-05 1996-05-28 Eli Lilly And Company 5-HT1F agonists for the treatment of migraine
US5521197A (en) * 1994-12-01 1996-05-28 Eli Lilly And Company 3-<1-alkylenearyl>-4-<1,2,3,6-tetrahydropyridinyl>-and 3-<1-alkylenearyl>-4-piperidinyl-1h-indoles: new 5-HT1F agonists
CN1184425A (zh) 1995-03-20 1998-06-10 伊莱利利公司 5－取代－3－(1,2,3,6－四氢吡啶－4－基)－和3－(哌啶－4－基)－1h－吲哚:新型5－ht1f激动剂
CA2234166A1 (en) 1995-10-10 1997-04-17 Patric James Hahn N-¬2-substituted-3-(2-aminoethyl)-1h-indol-5-yl|-amides: new 5-ht1f agonists
US5708187A (en) * 1996-06-27 1998-01-13 Eli Lilly And Company 6-substituted-1,2,3,4-tetrahydro-9H-carbazoles and 7-substituted-10H-cyclohepta 7,6-B!indoles: New 5-HT1F agonists
EA001912B1 (ru) 1996-08-28 2001-10-22 Эли Лилли Энд Компани Замещенные 1,2,3,4-тетрагидро-2-дибензофуранамины
CA2268164A1 (en) 1996-10-08 1998-04-16 Yao-Chang Xu New serotonin 5-ht1f agonists
ZA979961B (en) 1996-11-15 1999-05-05 Lilly Co Eli 5-HT1F agonists
EP0875513A1 (en) 1997-04-14 1998-11-04 Eli Lilly And Company Substituted heteroaromatic 5-HT 1F agonists
ID23053A (id) 1997-06-04 2000-01-20 Lilly Co Eli Karboksamida yang digunakan sebagai agonis 5-ht <if>
US5905084A (en) 1997-11-14 1999-05-18 Eli Lilly And Company 5-HTIF -agonists effective in treating migraine
AU4961499A (en) 1998-06-26 2000-01-17 Eli Lilly And Company 5-HT1f agonists
JP2002519348A (ja) 1998-06-30 2002-07-02 イーライ・リリー・アンド・カンパニー ５−ｈｔ１ｆアゴニスト
WO2000034266A1 (en) 1998-12-11 2000-06-15 Eli Lilly And Company Indole derivatives and their use as 5-ht1f agonists
BR0008112A (pt) * 1999-02-10 2001-11-13 Lilly Co Eli Agonistas de 5-ht 1f
HUP0200245A2 (en) 1999-02-26 2002-06-29 Lilly Co Eli Furo[3,2-b]pyridines as 5-ht1f agonists and pharmaceutical compositions containing them and their use
WO2001068585A1 (fr) * 2000-03-14 2001-09-20 Fujisawa Pharmaceutical Co., Ltd. Nouveaux composes amides
TWI263497B (en) * 2002-03-29 2006-10-11 Lilly Co Eli Pyridinoylpiperidines as 5-HT1F agonists
JP2006523692A (ja) * 2003-04-18 2006-10-19 イーライ リリー アンド カンパニー ５−ｈｔ１ｆ作用薬としての（ピペリジニルオキシ）フェニル、（ピペリジニルオキシ）ピリジニル、（ピペリジニルスルファニル）フェニル、および（ピペリジニルスルファニル）ピリジニル化合物
UA82711C2 (en) * 2003-09-12 2008-05-12 Эли Лилли Энд Компани Substituted 2-carbonylamino-6-piperidinaminopyridines and substituted 1-carbonylamino-3-piperidinaminobenzenes as 5-ht1f agonists

Also Published As

Publication number Publication date
PL1663971T3 (pl) 2012-05-31
EP1663971A1 (en) 2006-06-07
AU2004280320A1 (en) 2005-04-21
ATE538093T1 (de) 2012-01-15
MA28212A1 (fr) 2006-10-02
AR045619A1 (es) 2005-11-02
TWI340740B (en) 2011-04-21
IL173521A (en) 2012-10-31
TW200521113A (en) 2005-07-01
MXPA06002767A (es) 2006-06-14
AU2004280320B2 (en) 2010-02-18
MY144623A (en) 2011-10-14
BRPI0414241A (pt) 2006-11-07
WO2005035499A1 (en) 2005-04-21
UA82711C2 (en) 2008-05-12
US7803813B2 (en) 2010-09-28
CN1849307B (zh) 2011-08-03
IL173521A0 (en) 2006-07-05
US20070270466A1 (en) 2007-11-22
CA2537936C (en) 2013-03-12
ECSP066415A (es) 2006-09-18
NZ545049A (en) 2009-06-26
US20060287363A1 (en) 2006-12-21
EA200600570A1 (ru) 2006-12-29
US20110034511A1 (en) 2011-02-10
US7291632B2 (en) 2007-11-06
JP4700614B2 (ja) 2011-06-15
ES2379665T3 (es) 2012-04-30
KR100777875B1 (ko) 2007-11-28
KR20060087554A (ko) 2006-08-02
CR8275A (es) 2006-06-06
PE20050350A1 (es) 2005-05-17
DK1663971T3 (da) 2012-03-19
CY1112475T1 (el) 2015-12-09
PT1663971E (pt) 2012-03-21
CN1849307A (zh) 2006-10-18
EP1663971B1 (en) 2011-12-21
CA2537936A1 (en) 2005-04-21
SI1663971T1 (sl) 2012-05-31
JP2007505105A (ja) 2007-03-08
ZA200602072B (en) 2007-09-26
EA011274B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
NO20061584L (no) Substituerte 2-karbonylamino-6-piperidinaminopyridiner og substituerte 1-karbonylamino-3-piperidinaminobenzener som 5-HT1F agonister
MY134666A (en) Pyridinoylpiperidines as 5-ht1f agonists
NO20085269L (no) 2-tioksantinderivater som fungerer som MPO-inhibitorer
TW200800938A (en) Indole carboxylic acid derivatives exhibiting PGD2 receptor antagonism
TW200745029A (en) Sulfonamide derivatives exhibiting PGD2 receptor antagonism
MY142807A (en) Benzimidazole derivative and use thereof.
NO20062704L (no) Azabicykliske heterocykler som cannabinoide reseptormodulatorer
HRP20070430T3 (en) (3-oxo-3,4-dihydro-quinoxalin-2-yl-amino)-benzamide derivatives and related compounds as glycogen phosphorylase inhibitors for the treatment of diabetes and obesity
NO20092286L (no) Nitrogenhaldige heterosykliske forbindelser og anvendelse derav
NZ561747A (en) (Pyrrol-2-ylmethyl)-indol-1-yl-acetic acid derivatives with PGD2 antagonist activity
TW200734322A (en) Indole derivatives exhibiting PGD2 receptor antagonism
CO6160323A2 (es) Derivados de quinazolinona 5-sustituidos como agentes antitumorales
TW200744587A (en) Azaindole derivatives exhibiting PGD2 receptor antagonism
HRP20020175B1 (en) N-heterocyclikc derivatives as nos inhibitors
NO20091889L (no) Inhibitorer av spiroketon acetyl-CoA karboksylase
NO20092050L (no) Nye sulfonamidderivater som bradykininantagonister
TW200745058A (en) MMP-13 selective inhibitors
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
MX2010001566A (es) Derivado de aminopirazolamida.
NO20043951L (no) 3-cyklyl-5-(nitrogenholdig 5-leddet ring) metyl-oksazolidinon-derivater og deres anvendelse som antibakterielle midler
DE602006010702D1 (de) Homomorpholinoxazolidinone als antibakterielle mittel
NO20071230L (no) Oksazolidinoner inneholdende oksindoler som antibakterielle midler
HUP0303020A2 (hu) Androgén 7-szubsztituált 11-halogénezett szteroidok, eljárás az előállításukra, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
NO20080285L (no) Alfa-(aryl- eller heteroarylmetyl)-beta-piperidinopropionsyreforbindelser som ORL-1-reseptorantagonist

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application